RevitalVision announced new clinical evidence that demonstrates the effectiveness and safety of its perceptual learning software in improving visual function across multiple ophthalmic indications. The findings, based on 6 randomized controlled trials completed in 2025, highlight meaningful improvements in visual acuity, contrast sensitivity, and binocular function that demonstrates the brain’s ability to adapt through synaptic and functional neural plasticity. A seventh study further confirmed the long-term stability of visual improvements in patients with amblyopia over a 5-year period, the company said in a press release. 

Results published in the American Journal of Ophthalmology demonstrated that patients with stable keratoconus who trained using RevitalVision achieved an average improvement of 1.7 lines in best-corrected visual acuity, compared to no improvement in the control group (P<0.0006). Nearly half of treated patients also showed improvements in stereoacuity, along with significant gains in contrast sensitivity.

A randomized controlled trial published in the British Journal of Ophthalmology showed that patients aged 9 to 55 with infantile nystagmus experienced significant improvements in both distance and near visual acuity. Distance visual acuity improved by 1.1 lines, near visual acuity improved by 2 lines, 46% of patients reached vision levels sufficient for driving, and 76% reported they would recommend the treatment. Patients in the control group who later crossed over to active treatment also demonstrated substantial improvement.

A long-term follow-up study published in the Latin American Journal of Ophthalmology demonstrated sustained benefits in patients with amblyopia aged 8 to 40. Participants achieved an average improvement of more than 2 lines in visual acuity, and results remained stable over 5 years (P<0.001).

The company also noted that 3 additional randomized controlled trials presented at ASCRS 2025 received the Best Scientific Paper Award in their sessions. These studies demonstrated significant improvements in patients with keratoconus and in postcataract surgery patients who were implanted with multifocal intraocular lenses and experienced neuroadaptation difficulties, the company said.

In addition, RevitalVision’s technology showed promising results in sports vision with professional soccer players from the Belgian Premier League club Standard Liège. Players' visual acuity improved from 20/20 to 20/15 and they experienced significant improvements in contrast sensitivity, the company said.

“These results provide strong evidence that the adult brain retains residual neuroplasticity that can be leveraged to improve visual performance,” said Yair Yahav, CEO of RevitalVision, in the press release. “Utilizing RevitalVision for a gain of visual function is akin to prescribing physical therapy postsurgery or for injury recovery."